Company news

Oncoinvent ASA news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Oncoinvent ASA - Disclosure of large shareholding

September 23, 2026

Oncoinvent ASA - Mandatory notification of trade - Allocation and share lending in Private Placement

September 22, 2026

Oncoinvent ASA - Mandatory notification of trade

September 22, 2026

Oncoinvent ASA - Key information relating to subsequent offering

September 22, 2026

Oncoinvent ASA - Successful Private Placement and Retail Offering

September 22, 2026

Oncoinvent ASA - Contemplated private placement and retail offering

September 22, 2026

Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine

August 11, 2026

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin[®]

June 18, 2026

Oncoinvent ASA: Grant of share options to member of the Board following AGM

May 20, 2026

Oncoinvent ASA: Share capital decrease completed

May 5, 2026

Oncoinvent presents corporate update in live webcast

April 29, 2026

Oncoinvent ASA: Notice of Annual General Meeting

April 28, 2026

Oncoinvent ASA: Invitation to business update Wednesday 29 April 2026

April 23, 2026

Oncoinvent ASA: Annual Report for 2025

April 22, 2026

Oncoinvent secures new patent expanding protection for Radspherin[®]

March 19, 2026

Oncoinvent ASA: Grant of share options to the CEO

March 11, 2026

Oncoinvent ASA: Second half 2025 results

February 26, 2026

Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026

February 17, 2026

Oncoinvent ASA, Announces webcast presentation of second half 2025 results on Thursday 26 February 2026

February 16, 2026

Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026

February 16, 2026

Four additional sites open for recruitment in Oncoinvent's Phase 2 trial

January 29, 2026

Oncoinvent ASA: Registration of reverse share split

January 20, 2026

Oncoinvent ASA: Ex. reverse share split and change of ISIN today

January 19, 2026

Oncoinvent ASA, Key information relating to the reverse share split and Change of ISIN

January 15, 2026

Oncoinvent ASA - New share capital registered

January 15, 2026

Oncoinvent ASA: Key information relating to the reverse share split and change of ISIN

January 14, 2026

Oncoinvent ASA, Grant of share options to new CFO

January 14, 2026

Oncoinvent ASA: Grant of share options to new CFO

January 13, 2026

Oncoinvent ASA: Grant of share options – mandatory notification of trade

December 22, 2025

Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer

October 8, 2025

Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

August 27, 2025

Announcement of fully underwritten rights issue

June 30, 2025

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks

The 5 newest of 26 decks. Every deck is listed under its year.